# Iofina Plc a ‘Buy’ on Robust Pricing and Further Customer Demand, Alex Brooks, Canacccord

- Link: https://www.directorstalkinterviews.com/iofina-plc-a-buy-on-robust-pricing-and-further-customer-demand-alex-brooks-canacccord/4121185978
- Published: 2025-02-07T07:59:36+00:00
- Author: Anthony Fox

**Iofina plc** (LON:IOF), a leading specialty chemicals company focused on iodine
production, has delivered record-breaking production results in 2024, reinforcing
its position as a key player in the market. According to Canaccord Genuity’s latest
research note, Iofina produced an impressive 634 tons of iodine for the year—a 13%
increase from 2023. The firm remains on track for even greater expansion, with production
for the first half of 2025 expected to rise between 16% and 29% year-on-year.

### **Demand Remains Strong**

Iodine market conditions remain robust, with prices holding steady above $70/kg.
Canaccord Genuity analysts highlight that demand remains particularly strong for
antimicrobial IPBC, with sales significantly surpassing 2023 levels. This trend 
is expected to continue, underpinning Iofina’s growth prospects across multiple 
end markets.

### **Future Growth Prospects Look Bright**

Iofina’s expansion strategy is progressing well, with its latest iodine plant, IO#
10, fully operational. Construction of IO#11 is underway and is expected to come
online in Q3 2025, while discussions for IO#12 are advancing positively. Canaccord
Genuity forecasts Iofina’s production to reach 775 tons in 2025, reflecting a 23%
year-on-year increase, with further growth of over 20% expected in 2026.

By the end of 2026, Iofina is projected to achieve a production run rate close to
1,000 tons per annum, fulfilling its long-term target.

### **Short-Term Hurdles, Long-Term Strength**

Despite the strong operational performance, Iofina faced minor shipment delays at
the end of 2024, which caused $2 million in revenue to be recognised in January 
2025 instead of December. This adjustment has led to a revised 2024 EBITDA estimate
of $7.5 million (previously $8.6 million). However, Canaccord Genuity does not view
this as material, noting that “management expect the $1mn EBITDA to be recognised
in 2025E, for prudence we have made no change to this year’s forecast.”

### **Canaccord Genuity Maintains ‘BUY’ Rating**

With a solid production outlook and strong iodine demand, Canaccord Genuity reiterates
its ‘BUY’ rating on Iofina, maintaining a target price of 37.5p. The report values
the stock at 10x and 8x EV/EBITDA for 2025 and 2026, respectively, and sees the 
company well-positioned to capitalise on further market opportunities.

### **Final Thoughts**

Iofina continues to demonstrate its ability to scale up production while maintaining
strong market demand. The successful commissioning of new plants and a positive 
pricing environment suggest a promising future for the company. While short-term
dispatch delays impacted 2024’s final numbers, the long-term growth trajectory remains
firmly intact. Investors should watch Iofina closely as it moves towards achieving
its ambitious production goals.

Share on:
